Inivata is attending The Molecular Medicine Tri Conference Feb 19-24, San Francisco
Davina Gale, an Inivata co-founder and Business Development Manager is attending The Molecular Medicine Tri Conference Feb 19-24 in San Francisco. Davina will also be joining a workshop with Horizon Discovery entitled ‘Enabling Sequencing Technologies to Reach Their Full Potential – bringing ctDNA to the clinic’ taking place in room #130 on Tuesday 21st February, 3:40-4:10pm. If you would like to meet with Davina during the conference please contact us.
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.
Consilium Strategic Communications
Chris Gardner/Angela Gray/Sarah Wilson
Paul Rabin (US)
firstname.lastname@example.org +44 (0)20 3709 5700, +1 516 503 0271
email@example.com +44 (0)7900 430235